Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection

Regueiro, Miguel; Schraut, Wolfgang H.; Baidoo, Leonard; Kip, Kevin E.; Sepulveda, Antonia R.; Pesci, Marilyn; Harrison, Janet; Plevy, Scott E.

doi:10.1053/j.gastro.2008.10.051

Cited by 539 publications

(340 citation statements)

References 29 publications

Supporting

Mentioning

327

Contrasting

Unclassified

Order By: Relevance

“…31,32 Allowing for a 31% drop-out of patients 170 patients (113 active and 57 standard care arms) were needed. The sample size for the study was based on the clinical study design comparing M A N U S C R I P T…”

Section: Discussionmentioning

confidence: 99%

“…32 The outcomes observed using other endoscopic scoring systems provide support for the primary measure used in this study (Rutgeert's score). Although the Crohn's Disease Endoscopic Index of Severity (CDEIS) 28 and the Simple Endoscopic Score for Crohn's Disease (SES-CD) 29 are not specific for the post-operative setting, they were used in the context of removal of all macroscopic disease.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

See 1 more Smart Citation

Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery

et al. 2015

View full text Add to dashboard Cite

and PV Desmond have no conflicts of interest to declare. P De Cruz has received travel grant support from Abbott and Schering-Plough. MA Kamm has acted as an advisor to Abbott and Janssen, has received research support from Abbott, and has acted as a speaker at symposiums sponsored by Abbott and Janssen. A Hamilton has received an educational grant from Abbott. D Liew has served on advisory boards and received research grants from Abbott. IC Lawrance has been on an advisory board for Abbott and Janssen, a speaker for Abbott and Janssen, and has held research and travel grants from Abbott and Janssen. JM Andrews has been an advisory board member for both Janssen and Abbott, spoken for both Abbott and Janssen, received research funds from both Abbott and Janssen, and received travel grants from both Abbott and Janssen. PA Bampton has been on advisory boards for Janssen and Abbott, has received research funding from Abbott, and travel sponsorship from both Abbott and Janssen. PR Gibson has received consulting fees from Abbott, Janssen, and Schering-Plough; research support from Abbott; and payments for lectures from Abbott and Janssen. FA Macrae has been on an advisory board to Janssen, has received travel grants from Abbott, and has received clinical research support from Janssen, Abbott and MSD. W Selby has been on an advisory board for Abbott. SJ Bell has received travel assistance from Abbott. SJ Brown has received travel support and speaker fees from both Abbott and Janssen. WR Connell has been on advisory board for Janssen and a speaker for Abbott and Janssen. AS Day has been an M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT advisor to Janssen. RB Gearry has been on an advisory board for Abbott and Janssen, a speaker for Abbott and Janssen, and held research, educational and travel grants from Abbott and Janssen.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Accepted Manuscriptmentioning

confidence: 99%

Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Infliximab therapy significantly improved endoscopic inflammation and reduced the risk of subsequent clinical recurrence. In contrast, recent randomized controlled trials (RCTs) found that anti-TNF therapy with infliximab or adalimumab initiated soon after surgery was useful in preventing postoperative recurrence in CD [9][10][11]. Should we start anti-TNF therapy soon after surgery or after confirming early endoscopic recurrence?…”

mentioning

confidence: 75%

Prevention of Postoperative Recurrence in Crohn’s Disease

Yamamoto

2014

Drugs

View full text Add to dashboard Cite

“…24 There are not yet comparative effectiveness data for thiopurines and TNF antagonists for the indication of prevention of post-operative recurrence, but early data suggest a very large effect size for TNF antagonists. 25,26 If TNF antagonists had a similar low cost as generic thiopurines, there would likely be little debate regarding an evolution towards treatment of CD with TNF antagonists, either as monotherapy or ideally as combination therapy. Unfortunately, this is not the world that we live in.…”

mentioning

confidence: 99%